Latest:
Dr Spigel on a 14-Gene Assay for Clarifying the Benefit of Adjuvant Chemo in NSCLC
David Spigel, MD, discusses the potential clinical effect of a 14-gene molecular assay for identifying candidates for adjuvant chemotherapy in NSCLC.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
David R. Spigel, MD, Sarah Cannon Research Institute
Latest:
Rapid Readouts: Updated Results and 5-Year Survival Outcomes From the PACIFIC Trial
David R. Spigel, MD, presents data from the 2021 American Society of Clinical Oncology annual meeting on the updated results from the phase 3 PACIFIC trial of durvalumab treatment after chemotherapy in patients with unresectable stage III non-small cell lung cancer
David Reardon, MD, Dana-Farber Cancer Institute
Latest:
Rapid Readouts: Results of the SCOUT and NAVIGATE Trials
David A. Reardon, MD, presents slides, shown at the 2021 American Society of Clinical Oncology Annual Meeting, from the phase 2 NAVIGATE basket trial and the phase 1/2 SCOUT trial in adult and pediatric patients with tropomyosin receptor kinase (TRK) fusion–positive primary central nervous system (CNS) tumors treated with larotrectinib with or without prior therapy.
David Ross Camidge, MD, PhD
Latest:
Dr. Camidge on Biomarker Combinations in NSCLC
David Ross Camidge, MD, PhD, professor, Division of Medical Oncology, Joyce Zeff Chair in Lung Cancer Research, School of Medicine, Division of Medical Oncology, University of Colorado, discusses biomarker combinations in non–small cell lung cancer (NSCLC).
David S. Hong, MD
David S Hong, MD is Deputy Chair of the Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
Latest:
Dr Hong on the FDA Approval of Larotrectinib for NTRK+ Solid Tumors
David S. Hong, MD, discusses the FDA’s full approval of larotrectinib for patients with solid tumors harboring an NTRK gene fusion.
David S. Siegel, MD, PhD
David S. Siegel, MD, is the chief of the Division of Multiple Myeloma at the John Theurer Cancer Center at Hackensack University Medical Center in New Jersey.
Latest:
Dr Siegel on the Evaluation of Mezigdomide for R/R Myeloma
David S. Siegel, MD, explains the rationale for assessing mezigdomide—a novel thalidomide derivative—in relapsed/refractory multiple myeloma.
David T. Marshall, MD
Latest:
Dr. Marshall on ASCENDE-RT Trial for Prostate Cancer
David T. Marshall, MD, MS, professor, director, Medical Residency Program, Department of Radiation Oncology, Medical University of South Carolina, discusses the ASCENDE-RT trial, which compared dose-escalated external beam radiation therapy versus low-dose-rate brachytherapy for men with unfavorable-risk localized prostate cancer.